| P Schultz, Pharm.D., K Moran, Pharm.D., T Hogan, Pharm.D., K Malcolm, Pharm.D., M Zenni, M.D.; Resident, Department of Pharmacy Background: Rising medication costs have led health care organizations to pursue alternatives to conventional medication dosing in hopes of decreasing drug expenditures. Patients are being asked to split tablets to receive the proper dose of medications at a lower cost. The atorvastatin 40 mg tablet is not scored, yet an increasing number of patients are splitting these tablets to receive a dose of 20 mg per day. In addition, alternate day dosing of atorvastatin 40 mg may provide similar therapeutic results at a lower cost to the patient and health care organization. The objective of this study is to compare three different methods of administering atorvastatin with respect to efficacy, cost savings and patient acceptance. Methods: The study is a prospective, randomized, open label, crossover clinical trial. Consenting patients meeting criteria were randomized to one of three treatment arms atorvastatin one whole 20 mg tablet daily, one-half 40 mg tablet daily or one whole 40 mg tablet every other day ; , with each treatment arm lasting six weeks. At the end of each treatment arm, labs were obtained and questionnaires administered before crossing over into the subsequent arm. Lipid values were compared to determine if there was a difference in therapeutic effect. Potential cost savings and patient acceptance were also evaluated. Results: Twenty-nine patients were enrolled in the study. Data collection is ongoing. To date, no trends have been identified to indicate a therapeutic difference in the three dosing regimens being compared. Additionally, the majority of patients have not expressed difficulty in following the alternative dosing regimens. Based on the 29 patients enrolled, a cost savings of $976 per month, or $11, 712 per year may be realized by utilizing one of the alternative regimens.
Hypertension - the risk charts are based on people who are previously untreated. If currently being treated the risk is higher than indicated on charts. Higher risk than shown in charts and for hypertriglycerideamia the first choice formulary statin is atorvastatin.
Nr. Autoren The Long-Term Intervention with Pravastatin in Ischaemic Disease LIPID ; Study Group. Titel Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of intial cholesterol levels. MRC BHF Heart Protection Study of cholesterol lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death early safety and efficacy experience. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS TexCAPS. Air Force Texas Coronary Atherosclerosis Prevention Study. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study 4S ; . The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial-Lipid Lowering Arm ASCOT-LLA ; : a multicentre randomised controlled trial. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. Pravastatin in elderly individuals at risk of vascular disease PROSPER ; : a randomised controlled trial. Publikationsort.
Atorvastatin therapy
For absorption carrier sites in the small intestine and slow the movement of L-DOPA into the blood stream. Pharmacokinetic data substantiate that the administration of L-DOPA with food delays absorption and reduces peak plasma concentrations. Dietary amino acids can also compete with L-DOPA for active transport sites at the blood brain barrier. Consequently, the therapeutic effects of intravenously administered L-DOPA can also be influenced by diet 5 ; . The side effect profile of L-DOPA can be categorized into early and late occurring events. The most common side effects that occur early in therapy are nausea and vomiting. Hypotension and cardiac arrhythmias are also possible in the initial days of therapy but are not as common. These initial side effects are peripheral in origin i.e., do not involve the CNS ; and are mediated by dopamine. L-DOPA itself has few, if any, pharmacological actions. Therefore, these side effects can be reduced or eliminated by the addition of a peripheral inhibitor of AAADC, the enzyme that coverts LDOPA to dopamine see below ; . Alternatively, administration of vitamin supplements containing vitamin B6 pyridoxine ; , a cofactor for AAADC, will increase the peripheral conversion of L-DOPA to dopamine resulting in more side effects and a reduced therapeutic effect. Side effects that occur later in therapy 2-4 months ; include nightmares, hallucinations, psychosis and abnormal, involuntary movements such as dyskinesia or dystonia. These delayed side effects are of central origin and occur following administration of relatively high doses. Consequently, these side effects cannot be alleviated by the addition of a peripheral inhibitor of AAADC but instead are reversed or controlled by reducing the dose. This can be problematic given that reducing the dose may result in loss of some of the beneficial effects of therapy 9 ; . During the first few years of L-DOPA therapy, the patient usually has smooth, day-long control of the symptoms. However, as the disease progresses, problems begin to arise. During the course of the day, the patient may experience "peak-dose dyskinesia" which are involuntary movements occurring at the time of peak plasma levels - too much dopamine. Later in the day, the patient may experience "end-of-dose hypokinesia"; Parkinsonian symptoms occurring at the time of low or subtherapeutic plasma concentration. These changes are referred to as the "on-off phenom, for example, atorvastatin pharmacokinetics.
27. Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics. Part II of a series. J Dent Assoc 1999; 130 2 ; : 236-51. 28. Moore, PA, Gage, TW, Hersh, EV, et. al., Adverse Drug Interactions in Dental Practice: Professional and Educational Implications. Part I of a series. J Dent Assoc 1999; 130 2 ; : 47-54. 29. Schwartz JB. Clinical Pharmacology. In: Hazzard WR, Blass JP, Ettinger WH, et al eds. Principles of Geriatric Medicine and Gerontology, Fourth Edition. USA: McGraw Hill; 1999: 303-331. 30. Merck Manual of Geriatrics, Third Edition. Beers MH and Berkow R, eds. Whitehouse Station, New Jersey, Merck Research Laboratories: 2000; 54-74. 31. Logue RM. Self Medication and the Elderly: How technology can help. AJN 2002; 102 7 ; : 51-55. 32. Geriatric Dosage Book, 9th Edition . Semla TP, Beizer JL, Higbee MD eds. Hudson Ohio; Lexicomp: 2003; 21, 315. : pdrhealth index 34. : mcp herbal default htm 35. Ang-Lee MK, Moss J, Yuan CS. Herbal Medicines and Peri-operative Care. JAMA 2001; 286 2 ; : 208-216 36. Miller LG. Herbal Medicinals: Selected Clinical Considerations Focusing on Known Potential Drug Interactions. Archives of Internal Medicine 1998; 9: 158 ; : 2200-2211. 37. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, Part III in a series. Journal of the American Dental Association 1999; 130 3 ; : 397-407. 38. Hersh EV, Moore PA. Drug interactions in Dentistry: The Importance of Knowing your CYPs. JADA 2004; 135: 298-311. Meredith MJ, Herbal nutriceuticals: a primer for dentists and dental hygienists. J Contemp Dent Pract 2001; 2 ; 2: 001-024. 40. : nlm.nih.gov medlineplus drugsinfo medmaster a686002 41. Abdollahi M, Radfar M. A review of drug induced oral reactions. J Contemp Dent Pract 2003 4 ; 1: 010-031. 42. Chronic Renal Failure and Dialysis In: Little JW, Falace DA, Miller CS, eds. Dental Management of the Medically Compromised Patient, Sixth Edition. St. Louis MO: Mosby: 2002; 147-160. 43. Moore PA. Adverse drug interactions in dental practice: interactions associated with local anesthetics, sedatives and anxiolytics. Part IV of a series. Journal of the American Dental Association 1999; 130 4 ; : 541-54. 44. Yagiela J. Adverse Drug Interactions in Dental Practice: Interactions Associated with Vasoconstrictors. Part V of a series. Journal of the American Dental Association 1999; 130 2 ; : 701-09. 45. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005 Apr 18; 182 8 ; : 413-5.
Medication-induced headaches can result from overuse of triptans and ergotamines but are particularly likely to result from overuse of these combination analgesics and axid.
Drugs such as azole antifungals, clarithromycin, cyclosporin a, erythromycin, grapefruit juice, macrolide antibiotics, mibefradil, and verapamil inhibit the cytochrome p450 3a4 system, interfere with the elimination of atorvastatin, cerivastatin, lovastatin, and simvastatin, and raise their serum levels.
Figure 3. Effects of RLPs and atorvastatin on integrin expression in U937 cells. A, U937 cells 1 106 mL ; were incubated in the presence of 15 g protein mL RLPs RLP ; or medium alone control ; for 18 hours, or pretreated with 10 mol L atorvastatin RLP atr ; for 48 hours before incubation with RLPs. Expression levels of integrins in U937 cells were analyzed by a flow cytometric analysis using monoclonal antibodies to CD11a, CD11b, CD18, CD49d, and L-selectin for each condition. Five thousands cells were analyzed. Data are representative of 4 separate experiments. B, Effect of antibodies to integrins on RLP-induced U937 cell adhesion under static conditions. RLP-treated U937 cells 2 106 mL ; were incubated with antibodies to the indicated integrins for 45 minutes and a static adhesion assay to HUVEC monolayers was performed. Data are from 4 separate experiments. * P 0.01 vs control; #P 0.05 vs RLP and azelaic.
Atorvastatin treatment
45 however, there are case reports of the development of myopathy when ezetimibe was added to high doses of atorvastatin or fluvastatin, 46 and in february 2005, a public advisory was issued in canada regarding myopathy as well as hepatitis, pancreatitis, and thrombocytopenia ; associated with the use of ezetimibe.
Nr. Autoren Titel The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20, 536 high-risk people: a randomised placebo-controlled trial. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. Safety and efficacy of enoxaparin vs unfractioned heparin in patients with NonST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial. The design of a prospective study of pravastatin in the elderly at risk PROSPER ; . Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerosis outcomes a LIPS substudy ; . White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol 70 mg dl and C-reactive protein 2 mg l. An analysis of the PROVE-IT TIMI-22 trial. Beneficial effect of early initiation of lipidlowering therapy following renal transplantation. Surrogat-Marker: Trugschlsse. Debate: The slippery slope of surrogate outcomes. The A-toZ trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Publikationsort and azithromycin.
543 is currently awaiting a hearing in the house health care council.
| Online PharmacyCOMPANY BRAND NAME Exjade 250 mg tablet Exjade 500 mg tablet Trileptal 150 mg tablet Trileptal 300 mg tablet Trileptal 600 mg tablet Novo Nordisk Canada Inc. Organon Canada Ltd AKZO ; Levemir Penfill 100 unit mL Andriol 40 mg capsule Advicor 500 20 520 mg tablet niacin lovastatin Advicor 1000 20 1020 mg tablet Niaspan 500 mg tablet Oryx Pharmaceuticals Inc. Niaspan 750 mg tablet Niaspan 1000 mg tablet Cubicin 500 mg vial Vantas 50 mg imp Paladin Labs Inc. Trelstar 3.75 mg vial Trelstar LA 11.25 mg vial Pfizer Canada Inc. Aricept RDT 5 mg tablet donepezil Aricept RDT 10 mg tablet Caduet 5 10 15 mg tablet Caduet 5 20 25 mg tablet Caduet 5 40 45 mg tablet Caduet 5 80 85 mg tablet Caduet 10 20 mg tablet Caduet 10 20 30 mg tablet Caduet 10 40 50 mg tablet amlodipine besylate atorvastatin calcium 02269465 02273233 02273241 Hypertension Cholesterol 30 Jan 2006 30 Jan 2006 30 Jan 2006 30 Jan 2006 30 Jan 2006 30 Jan 2006 30 Jan 2006 daptomycin * histrelin acetate * triptorelin pamoate * triptorelin pamoate * 02278383 02240000 02243856 Dementia 01 Mar 2006 niacin 02270447 02262347 02262355 Antibiotic Prostate Cancer Endometriosis Prostate Cancer Prostate Cancer 31 Oct 2006 14 Jul 2006 15 Aug 2006 15 Aug 2006 Under Review Within Guidelines Within Guidelines Within Guidelines Within Guidelines Within Guidelines Cholesterol 25 Apr 2005 patented 10 Jan 2006 ; Within Guidelines insulin detemir * testosterone undecanoate oxcarbazepine * CHEMICAL NAME DIN 02287439 02287447 02242067 Cholesterol 10 Jan 2006 Diabetes HRT hormone replacement therapy ; 03 Jan 2006 Nov 2004 patented 16 May 2006 ; Under Investigation Under Review Within Guidelines Epilepsy Apr 2002 patented 17 Jan 2006 ; THERAPEUTIC USE transfusion DATE OF FIRST SALE STATUS and azulfidine.
Other studies examining aggressive lipid lowering with atorvastatin include the recently launched incremental decrease in endpoint through aggressive lipid lowering ideal ; , the myocardial ischemia reduction with aggressive cholesterol lowering miracl ; trial and the reversal trial examining whether atherosclerotic regression is associated with aggressive ldl-c reduction.
Found that arthritic patients taking cholesterol lowering drug lipitor known chemically as atorvastatin, a class and bactrim.
Generic Atorvastatin
|
It is available as pills and injections for administration in your veins, for example, atorvastatin prescribing information.
What is Atorvastatin
Fit of the dose-response model for the reduction in LDL-C data for monotherapy with ezetimibe. Figure 3 shows the impact of 10 mg of ezetimibe on the statin dose-response relationship. A simple pharmacologically independent interaction between statins and ezetimibe was observed. The interaction coefficient g ; was not statistically significantly different from 1 and was, therefore, fixed to this pharmacological value. The dose-response relationship for gemcabene for the percentage of LDL-C reduction was well described by a sigmoidal Emax model. The Emax for gemcabene is about 35%, which is larger than the Emax for ezetimibe but smaller than the lipid-lowering effect produced by the statins. The model parameters for gemcabene are presented in Table 2. Figure 4 shows the fit of the dose-response model for the reduction in LDL-C data for monotherapy with gemcabene. Figure 5 shows the impact of different atorvastatin doses on the gemcabene dose-response relationship. The interaction coefficient g was significantly different from 1 p 0.001 ; suggesting a more complex interaction between gemcabene and statins than the simple independent pharmacological interaction that was observed between statins and ezetimibe. The interaction is actually less than independent, with g 5 1.69 6 mean 6 SE ; , resulting and bromocriptine.
Some professionals suggest reducing or eliminating intake of alcohol, caffeine, and tobacco while taking any psychiatric medication, for example, atorvastatin ramipril.
Although these respirators are disposable, if they are used strictlyfor tb control, they may be reused by the same healthcare worker as long as therespirator remains structurally intact or is not damaged or soiled and cabergoline.
Arts & culture related news: canadian federal court favours ranbaxy dismisses pfizer s application on atorvastatin patent ca 2 220 455 gnome 1 2 released gnome 2 release the latest release of gnome is here: gnome 2.
Pressure may increase and disrupt the blood--brain barrier on the venous side. We have attempted to avoid some of these variables by examining the effects of histamine on small portions of single pial venular capillaries in situ. This preparation allows both luminal and abluminal application of substances, enables the direct effects of histamine to be isolated from those brought about by changes in microvascular hydrostatic pressure, and allows diffusive permeability to be assessed without interference from convection Easton & Fraser, 1994 ; . Some of the findings reported here have been presented previously in a preliminary form Easton & Fraser, 1993; Sarker & Fraser, 1994 and cafergot.
Previous AMI ; , heart failure dilated LV & EF 30% on echo ; , dyslipidaemia, microalbuminuria Examination: overweight at 127 kgs WC 125 cms and BMI 45 ; , BP 160 90, mild SOA Pathology: HbA1c 10.5%, CC 55 mls min, ACR 27.5, chol 4.4, LDL 2.7, HDL 1.39 & trigs 0.6 Medications: lispro 12 units bd + and protaphane 42 + 38 pm, aspirin 150 mg od, metformin 1 g bd, lisinopril 20 mg od, frusemide 40 mg od, atofvastatin 10 mg nocte.
Thu september 20 2007 products by category allergy & asthma montelukast advair diskus anti depression fluoxetine prozac ; , zoloft , celexa cipramil ; anafranil , effexor , lexapro cipralex ; duloxetine , paroxetine sertraline pain relief imitrex imigran ; , zomig zolmitriptan ; , codeine aspirin dolmen ; , codeine paracetamol , effervescent cod-efferalgan ; gelocatil codeine , analgilasa codeine caffeine ; , fiorinal , dolgesic codeine , termalgin frenadol dextromethorphan with chlorpheniramine ; , disdolen , naproxen celebrex celecoxib ; , fludeten , gelocatil codeine , sumatriptan women's health nolvadex-d tamoxifen ; , premarin estrogen ; , clomid clomiphene citrate ; , arimidex anastrozole ; , risedronate , alendronate muscle relaxants carisoprodol mio-relax ; , baclofen , lioresal flexeril , yurelax cyclobenzaprine ; relaxibys men's health viagra sildenafil citrate ; , propecia levitra , proscar , generic viagra - caverta generic cialis , dutasteride , finasteride sedatives buspirone buspar ; sleep doxylamine dormidina ; , diphenhydramine soñ oror ; , sonata , zopiclone weight loss reductil meridia ; xenical orlistat ; other neurontin gabapentin ; , nexium esomeprazole ; proviron , gonadotropin , pregnyl , catapres, clonidine , dextromethorphan romilar ; , topamax topiramate ; , lipitor , campral acamprosate ; , zyban , sinemet carbidopa levodopa ; ephedrine , clenbuterol , tamiflu , atomoxetine , leflunomide , atorvastatih , simvastatin , rosuvastatin , inderal , amlodipine bupropion your catapres prescription drugs without the need for prescription or a prior doctor consultation and calan and atorvastatin.
It has been observed that in the rat intestinal epithelial cell line IEC18, phosphodiesterase inhibitor inhibits cell proliferation through modulation of TGF- expression Diab-Assef et al. 2002 ; . The prominent expression of PDE11A in different types of epithelial cells and its ability to regulate the level and duration of intracellular cAMP indicate it may participate in many of these functions. Although relatively few studies have investigated the expression and function of PDEs in endothelial cells, PDE15 have been identified in various types of endothelial cells and PDE3 and PDE4 inhibitors have been shown to decrease endothelial cell proliferation and the expression of adhesion molecules reviewed in Maurice et al. 2003 ; . Here we show that PDE11A is expressed in the endothelial cells of most of the tissues examined. Its role in endothelium function awaits further study. It is well recognized that high levels of cAMP can destroy various types of cancer cells in culture. However, most of the agents that can mimic cAMP action or produce the dramatic increase on cAMP concentrations are highly cytotoxic, precluding their use clinically. In comparison, PDE inhibitors that induce moderate cAMP accumulation also inhibit cancer cell proliferation. For example, elevation of cAMP by nonspecific PDE inhibitors hampers growth in several human prostatic cancer cell lines and induces terminal differentiation in some of the lines Bang et al. 1994; Goto et al. 1999 ; . Treatments with specific or nonspecific PDE inhibitors result in growth inhibition in small-cell lung carcinoma Shafer et al. 1998 ; , acute promyelocytic leukemia Guillemin et al. 2002 ; , and malignant glioma cells Chen et al. 2002 ; . Although PDE inhibitors might not kill enough cancer cells when used alone, a nonspecific PDE inhibitor could reduce the effective doses of other anti-cancer drugs, thus maintaining the efficacy and decreasing the toxicity Hirsh et al. 2004 ; . Other and newer PDE inhibitors could provide better specificity and efficacy and less side effects in cancer therapy. As PDE11A is expressed abundantly in multiple human carcinomas, it could be a potential target. In summary, we have studied the tissue distribution of PDE11A using IHC and found that it is expressed in smooth muscle cells, epithelial cells, endothelial cells, and several other types of cells in most of the tissues surveyed. Our results suggest that PDE11A could be involved in multiple physiological processes in various tissues through their ability to modulate cAMP and cGMP levels. A PDE11A-specific inhibitor could greatly facilitate the elucidation of its functional roles.
Major depressive disorder is common. It is managed in large part by the family physician. After all, there aren't enough psychiatrists available to treat most patients who develop a depressive disorder. The majority of patients don't achieve full remission with the first-line antidepressant medication. However, there are strategies available to family physicians for effectively managing most of their patients presenting with major depressive disorder. CME and capoten.
01 Atrovastatin Colivicchi129 3 40 Subtotal 95% CI ; 40 Total events: 3 treatment ; , 4 control ; Test for heterogeneity: NA Test for overall effect: z 0.36 p 0.72 ; 02 Pravastatin GISSI-P130 Subtotal 95% CI ; 31 2138 Total events: 31 treatment ; , 49 control ; 2138 Test for heterogeneity: NA Test for overall effect: z 2.02 p 0.04 ; Total 95% CI ; 2178 Total events: 34 treatment ; , 53 control ; Test for heterogeneity: 2 0.07, df 1 p 0.80 ; , I2 0% Test for overall effect: z 2.04 p 0.04.
Table 12 Urology: How well does the MAWT fit into the ranges of the Target Wait Time?.
The selected nine districts were from three regions East, Central and Midwest ; . The training districts were Sunsari, Dolakha and Bardia. Similarly, training plus peergroup discussion districts were Mahotari, Banke and Surkhet. The remaining three districts Ilam, Morang and Bara were control. The study did not provide any additional intervention, it was a follow-up assessment only. The baseline data included carbon copy of prescriptions of one month which was collected in the previous study, served as pre-intervention data for comparison Kafle et.al; 2001 ; . The data collected between six and twelve months after the intervention was used for comparison with the baseline. 6.2 Sample Selection The study was conducted in the following nine districts Sunsari, Dolakha, Bardia, Mahotari, Banke, Surkhet, Ilam, Morang and Bara ; where the previous study was conducted The study included following hill districts: Ilam, Dolakha and Surkhet. Similarly, the terai districts were: Morang, Sunsari, Bara, Mahotari, Banke and Bardia. The name of health posts and number of prescriptions collected from each health post in the baseline and the follow up assessment are presented in Table-I.
Table 2. NSAID categories and examples of preparations available, for instance, atorvastatinn dose.
Atorvastatin order
Peter M. Ravdin, Ph.D., M.D., Kathleen A. Cronin, Ph.D., Nadia Howlader, M.S., Christine D. Berg, M.D., Rowan T. Chlebowski, M.D., Ph.D., Eric J. Feuer, Ph.D., Brenda K. Edwards, Ph.D., and Donald A. Berry, Ph.D. age-adjusted incidence of breast cancer by an average of about 0.5% per year, a rise that was particularly evident among women who were 50 years of age or older2 Fig. 1 ; . Changes in reproductive factors, in the use of menopausal hormonereplacement therapy, in mammographic screening, in environmental exposures, and in diet have all been proposed to explain the trend. Of these factors, only the use of hormone-replacement therapy changed substantially between 2002 and 2003. In this report, we provide additional data from 2004 that show little change in breast-cancer incidence between 2003 and 2004. A comparison of incidence rates in 2001 with those in 2004 omitting the years in which the incidence was in the process of changing ; showed that the decrease in annual age-adjusted incidence was 8.6% 95% CI, 6.8 to 10.4 ; . The decrease in breast-cancer incidence began in mid-2002 and occurred shortly after the highly publicized series of reports from the randomized trial of the Women's Health Initiative, which reported a significant increase in the risks of coronary heart disease and breast cancer associated with the use of estrogenprogestin combination therapy.3 By the end of 2002, the use of hormonereplacement therapy had decreased by 38% in the United States, with approximately 20 million fewer prescriptions written in 2003 than in 2002.4, 5 The analyses we report here used information from the SEER Program of the National Cancer Institute NCI ; collected from nine cancer registries reporting on 9% of the U.S. population. Trends in the incidence of female breast cancer were age-adjusted to the standard population in the year 2000 and were adjusted for reporting delays. Joinpoint version 3.0 ; statistical software : srab ncer.gov joinpoint ; was used for fit and axid.
Ing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. J Cardiol 1997; 80: 347-8. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastaatin Evaluation and Infection Therapy PROVE IT ; -TIMI 22 trial. J Cardiol 2002; 89: 860-1. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb IIIa inhibition with orbofiban in patients with unstable coronary syndromes OPUS-TIMI 16 ; trial. Circulation 2000; 102: 149-56. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology Task Force on Clinical Data Standards Acute Coronary Syndromes Writing Committee ; . J Coll Cardiol 2001; 38: 2114-30. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986; 42: 50719. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering -- are they clinically relevant? Eur Heart J 2003; 24: 225-48. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 17118. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 10638. Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Coll Cardiol 2001; 37: 1284-8.
Avui dia, l'ensenyament semipresencial s una realitat. Cada vegada sn ms els centres d'estudis superiors que es valen dels ltims avenos tecnolgics per oferir la possibilitat de cursar estudis semipresencials. La Facultat de Cincies Humanes, Traducci i Documentaci de la Universitat de Vic fa temps que aposta per aquesta modalitat d'ensenyament que esdev imprescindible per a persones amb un perfil determinat: els "semis". Qui sn els "semis"? Els "semis" sn els nostres estudiants: l'alumnat semipresencial de la Llicenciatura de Traducci i Interpretaci. Sn mares i pares, treballadores i treballadors, persones d'aqu i d'all. Parlem de persones emprenedores amb fora de voluntat, autodisciplina i ganes d'aprendre. Hem de tenir en compte que la premisa fonamental d'aquesta modalitat s l'autoformaci. s per aquest motiu que el professorat de la UVic s'encarrega de motivar l'aprenentage de l'alumnat mitjanant la gesti del material didctic. En el cas de l'ensenyament de la traducci jurdica, partir d'aquesta premisa s essencial pel que fa al desenvolupament de les propostes didctiques. Sovint, aquestes propostes es basen en la terminologia, sens dubte, un element fonamental de la didctica de la traducci jurdica. Per traduir cal que l'alumnat es familiaritzi amb els termes propis de la disciplina en qesti. Quines sn les directrius que en garanteixen l'aprenentatge efectiu, real i veritable? A l'hora de desenvolupar activitats efectives i, alhora, atractives, el professorat es veu obligat a recrrer a la prpia creativitat. L'objectiu ha de ser amenitzar l'aprenentatge de la terminologia d'una disciplina que acostuma a resultar complicada i feixuga sense oblidar els objectius docents: potenciar la creativitat traductolgica, fomentar l'esperit crtic de l'alumnat, entendre conceptes jurdics bsics. L'elaboraci de les cinc activitats que us proposem tot seguit s'ha basat en un objectiu clar: fomentar l'estudi i l'aprenentatge de la traducci i la terminologia jurdiques. Es tracta d'activitats que han donat, i continuen donant, bons resultats a les nostres aules virtuals. L'activitat Hot words permet a l'alumnat determinar quins sn els termes jurdics ms adequats per a un context especialitzat mitjanant l's d'obres de referncia; Enigmatic law s una alternativa fresca per estimular la creativitat traductolgica i sintctica en un mbit que, sovint, no deixa lloc a la flexibilitat; In case you're wondering. vol satisfer la curiositat de l'alumnat, conscient que per traduir cal anar ms enll de la transposci de paraules; Chat time respon clarament a la voluntat d'afavorir i facilitar la interacci entre alumnat i professorat, per evidenciar la importncia de les relacions personals en l'mbit semipresencial i Projecting translation s una introducci al mn de informtica aplicada a la traducci, un element cada vegada ms important en un mn les innovacions tecnolgiques sn constants. Cinc alternatives innovadores per fer de la traducci diversi. No oblidem que if you're not enjoying, you're not learning.
The high drop-out rate because of an adverse event, or the patient's preference, or "other reasons" is disturbing. This occurred despite patients' knowledge that they were at high risk of recurrence and death. Dropouts would likely be higher still in primary care practice. Pravastatin has the advantage of not being significantly metabolized by the P450 system in the liver. Thus, concerns about interactions between pravastatin and concomitantly administered drugs is much less than with atorvastatin, which is metabolized by the P450 system. RTJ 4-4 EFFECTS OF CONJUGATED EQUINE ESTROGEN IN POSTMENOPAUSAL WOMEN WITH HYSTERECTOMY This study reports the conjugated equine estrogen CEE ; -alone phase of the Women's Health Initiative trial which was continued for 7 years. The burden of incident disease events was equivalent in the CEE-alone and placebo groups. There was no significant difference in risks other than a slight increase in incidence of stroke. The absolute excess was 12 additional strokes per 10 000 person-years. And an absolute reduction of hip fracture of 6 per 10 000 personyears. The estimated excess risk for all monitored events CHD, stroke, pulmonary embolism, colorectal cancer, hip fracture, and deaths from other causes ; . was a non-significant 2 events per 10 000 person-years. This differs importantly from the WHI trial of combined estrogen progestin in which the risk of CHD was significantly elevated. Women and their health-care professionals now have usable risk estimates for the benefit harm ratio of CEEalone in treatment of menopausal symptoms. "Women can be reassured that incidence of CHD and breast cancer is not increased at least for 6.8 years". But, the data reinforce that there is no overall benefit of CEE for chronic disease prevention. Nevertheless, CEE-alone cannot be recommended for disease prevention. CEE should be used only for menopausal symptoms at the smallest effective dose for the shortest possible time. The study reported a lower risk of breast caner in the CEE-alone group vs the placebo group. This is contrary to other observational studies in which risk of BC is increased. I believe clinicians should remain wary and should consider that HRT in any form increases risk of breast cancer. I believe risks of CEE-alone as well as combined estrogen progestin have been overemphasized, and that many women are being unnecessarily denied relief from their menopausal symptoms. RTJ 4-5 EFFECT OF VITAMIN D ON FALLS This meta-analysis of randomized, controlled trials concludes that vitamin D supplementation reduces risk of falling in elderly persons. Based on 5 of the trials in over 1200 persons, vitamin D, was associated with a reduction in rate of falls by 22%. In two studies, vitamin D plus calcium compared with calcium alone ; improved body sway by 9% within 2 months, and increased muscle function up to 11.
|
